Ads
related to: belimumab lupus nephritis fda approval timeline- BENLYSTA Dosing Options
Consider Her Schedule And Needs.
Discover The Option That Fits Her.
- What About BENLYSTA?
Could BENLYSTA Be Another Option?
See the Data, Dosing & Resources.
- BENLYSTA Video Library
See Video Stories From Peers &
Dig Into BENLYSTA Patient Profiles.
- But Why BENLYSTA?
See Clinical Trial Results & More
To Explore BENLYSTA For Yourself.
- Learn More About BENLYSTA
Learn More About BENLYSTA & See
If It's An Option For Your Patient.
- BENLYSTA Resource Center
Discover A Library Of Resources
Designed To Inform You. Learn More.
- BENLYSTA Dosing Options
Search results
Results From The WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
Belimumab: GlaxoSmithKline: active lupus nephritis [1] Osimertinib: AstraZeneca: adjuvant therapy after tumor resection in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations Ansuvimab: Ridgeback Biotherapeutics: Ebola Zaire
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
For premium support please call: 800-290-4726 more ways to reach us
The approval is based on a late-stage study in which PiaSky showed a 79.3% control in the destruction of red blood cells versus 79% for the standard-of-care eculizumab from week 5 to week 25.
Kezar was testing the drug in patients with active lupus nephritis, which causes inflammation and damage in the kidneys due to a form of immune-related condition called lupus.
Ads
related to: belimumab lupus nephritis fda approval timeline